Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board’s Unanimous Recommendation that Stockholders Vote ...
Hosted on MSN
Pacira outlines growth potential with $725M-$765M 2025 revenue target and EXPAREL expansion to 2039
CEO Frank Lee highlighted the company's strategic "5x30" plan, emphasizing two key objectives: accelerating growth in their commercial business and advancing innovative assets, particularly PCRX-201.
Pacira outlines $745M–$770M 2026 revenue target as 5x30 strategy drives margin and pipeline progress
CEO Frank Lee indicated that Pacira entered 2025 with significant uncertainty around EXPAREL’s exclusivity, inconsistent margins, and pipeline visibility, but now reports "a clear strategic direction, ...
The presentation emphasized Pacira’s 5x30 growth strategy and significant patent litigation settlement for EXPAREL, which establishes exclusivity through 2039. This comes as the company positions ...
Pacira BioSciences, Inc. has announced a $300 million share repurchase authorization as part of its commitment to enhancing shareholder value and advancing its strategic 5x30 plan, which aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results